Christopher Ogden

Insider Reports History

Entity
Individual
Location
C/O Cytomx Therapeutics, Inc., 151 Oyster Point Blvd., Suite 400, South San Francisco, CA
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Christopher Ogden
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Christopher Ogden:

Stock Role Class Num Shares Value Price $ Report Date Ownership
CytomX Therapeutics, Inc. Chief Financial Officer Common Stock 108K $133K $1.23 Aug 20, 2024 Direct
CytomX Therapeutics, Inc. Chief Financial Officer Performance Stock Units (PSUs) 0 $0 $1.23 Aug 20, 2024 Direct
CytomX Therapeutics, Inc. Chief Financial Officer Stock Option (Right to Buy) 75K Jun 12, 2024 Direct

Insider Reports Filed by Christopher Ogden

Symbol Company Period Transactions Value $ Form Type Date Filed Role
CTMX CytomX Therapeutics, Inc. Aug 20, 2024 3 -$2.44K 4 Aug 22, 2024 Chief Financial Officer
CTMX CytomX Therapeutics, Inc. Jun 12, 2024 2 $0 4 Jun 14, 2024 Chief Financial Officer
CTMX CytomX Therapeutics, Inc. Mar 19, 2024 1 -$6.2K 4 Mar 21, 2024 SVP, Finance and Accounting
CTMX CytomX Therapeutics, Inc. Jan 18, 2024 3 $0 4 Jan 19, 2024 SVP, Finance and Accounting
CTMX CytomX Therapeutics, Inc. Dec 20, 2023 1 -$2.75K 4 Dec 22, 2023 SVP, Finance and Accounting
CTMX CytomX Therapeutics, Inc. Dec 17, 2023 2 $0 4 Dec 19, 2023 SVP, Finance and Accounting
CTMX CytomX Therapeutics, Inc. Mar 16, 2023 1 -$1.02K 4 Mar 20, 2023 SVP, Finance and Accounting
CTMX CytomX Therapeutics, Inc. Feb 2, 2023 3 $0 4 Feb 6, 2023 SVP, Finance and Accounting
CTMX CytomX Therapeutics, Inc. Aug 10, 2022 2 $0 4 Aug 12, 2022 SVP, Finance and Accounting
CTMX CytomX Therapeutics, Inc. Feb 14, 2022 0 $0 3 Mar 9, 2022 Interim Principal Accounting Officer